Spain and Portugal are emerging as attractive locations for biotech investment, driven by strong scientific foundations and evolving capital networks. Spain boasts a more developed startup ecosystem, particularly in regions like Catalonia, while Portugal is rapidly evolving, with a significant increase in biotech startups and initiatives like hosting the BIO-Europe Spring conference. Despite this progress, both countries face challenges in serial entrepreneurship, infrastructure for commercializing research, and bridging the funding gap between academic grants and early-stage investments. Overall, the Iberian Peninsula is becoming increasingly competitive in the biotech sector, with potential for growth and innovation.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/drug-development/beyond-sunshine-iberias-biotech-moment-has-arrived-with-developing-capital-networks
